{"id":"NCT01022424","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]","officialTitle":"A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2014-07","completion":"2014-07","firstPosted":"2009-12-01","resultsPosted":"2018-07-27","lastUpdate":"2018-09-11"},"enrollment":13,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Autosomal Dominant Polycystic Kidney Disease"],"interventions":[{"type":"DRUG","name":"OPC-41061","otherNames":[]}],"arms":[{"label":"OPC-41061","type":"EXPERIMENTAL"}],"summary":"ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening). Administration will be continued until the time of manufacturing and distribution approval of OPC-41061 for ADPKD in Japan.","primaryOutcome":{"measure":"Total Kidney Volume","timeFrame":"Baseline, Week 48, 96, 144, and 192","effectByArm":[{"arm":"Baseline","deltaMin":1428,"sd":null},{"arm":"Week 48","deltaMin":1675,"sd":null},{"arm":"Week 96","deltaMin":1728,"sd":null},{"arm":"Week 144","deltaMin":1775,"sd":null},{"arm":"Week 192","deltaMin":1901,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":13},"commonTop":["Nasopharyngitis","Blood antidiuretic hormone increased","Hypertension","Thirst","Back pain"]}}